Overview

Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA

Status:
Recruiting

Trial end date:
2022-03-30

Target enrollment:
0

Participant gender:
All

Summary

The haplotype HSCT system including Bu(0.8mg/kg Q6hx2d)CTX(50mg/kgx4d)rATG(2.5mg/kgx4d) , established in Institute of Hematology of Peking University ,has been evaluated to be effective for acquired SAA.But some patients with high risk factors may not tolerate CTX 200mg/kg,alternative conditioning regimen including Bu/Fludarabine/dercreased CTX was studied in this trial.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Thymoglobulin

Criteria

A：inclusion criteria

1. Patients diagnosed as acquired severe aplastic anemia(SAA) /very vSAA

2. patients with age 3-55 years

3. patients have no matched sibling donor

4. Patients have no matched unrelated donor

5. patients have no severe infection

6. Patients have no severe organ dysfunction

7. patients have risk factors of potential intolerance to previous condition regimen
including BuCy(200mg/kg)and ATG

8. Consent form signed

B. Exclusion criteria ：

1. patients with congenital SAA/vSAA

2. patients with age< 3years or >55 years

3. patients with matched sibling donor

4. patients with matched URD

5. patients with severe infection

6. patients with severe organ dysfunction

7. pregnancy women

8. no Consent form signed